UroGen Pharma Ltd. Ordinary Shares (URGN) Stock Price

URGNStock

$46.36+137.45%52W

Market Cap$2.27B

P/E—

PEG Ratio—

Div yield—

Beta1.54

URGN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)96.03%

Price vs S&P 500 (4W)9.86%

VGM Score63.42

Book Value / Share (Quarterly)$0.60

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)19.48%

Cash Flow / Share (Quarterly)$-3.26

Price vs S&P 500 (YTD)85.14%

Gross Margin (TTM)90.85%

Net Profit Margin (TTM)-51.73%

EPS (TTM)$-1.98

10-Day Avg Trading Volume1.10M

EPS Excl Extra (TTM)$-1.98

Revenue Growth (5Y)56.22%

EPS (Annual)$-3.19

ROI (Annual)-1319.29%

Gross Margin (Annual)88.66%

Net Profit Margin (5Y Avg)-161.00%

Cash / Share (Quarterly)$2.21

Revenue Growth QoQ (YoY)199.22%

ROA (Last FY)-76.57%

Revenue Growth TTM (YoY)100.27%

EBITD / Share (TTM)$-1.34

ROE (5Y Avg)-324.81%

Operating Margin (TTM)-35.32%

Cash Flow / Share (Annual)$-3.37

P/B Ratio95.19x

P/B Ratio (Quarterly)20.96x

Net Income / Employee (Annual)$-527,500

EV / Revenue (TTM)13.47x

Net Interest Coverage (TTM)-15.36x

ROA (TTM)-43.79%

EPS Incl Extra (Annual)$-3.19

Current Ratio (Annual)4.01x

Quick Ratio (Quarterly)3.20x

3-Month Avg Trading Volume0.85M

52-Week Price Return137.45%

Revenue / Employee (TTM)$648,600

Tangible BV / Share (Quarterly)$-1.36

P/S Ratio (Annual)22.12x

Asset Turnover (Annual)0.55x

52-Week High$50.81

Operating Margin (5Y Avg)-122.99%

EPS Excl Extra (Annual)$-3.19

CapEx CAGR (5Y)-25.03%

26-Week Price Return107.27%

Quick Ratio (Annual)3.34x

13-Week Price Return54.48%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.80x

Enterprise Value$2.54B

Revenue / Share Growth (5Y)33.32%

Asset Turnover (TTM)0.85x

Revenue / Employee (Annual)$377,300

Inventory Turnover (Annual)0.97x

Pretax Margin (Annual)-139.74%

Cash / Share (Annual)$2.49

3-Month Return Std Dev54.32%

Gross Margin (5Y Avg)88.98%

Net Income / Employee (TTM)$-335,500

ROE (Last FY)-1319.29%

Net Interest Coverage (Annual)-7.00x

EPS Basic Excl Extra (Annual)$-3.19

Receivables Turnover (TTM)3.48x

Total Debt / Equity (Quarterly)4.77x

EPS Incl Extra (TTM)$-1.98

Receivables Turnover (Annual)4.11x

ROI (TTM)-41.46%

P/S Ratio (TTM)12.87x

Pretax Margin (5Y Avg)-158.27%

Revenue / Share (Annual)$2.28

Tangible BV / Share (Annual)$-3.86

Forward P/E105.23x

Price vs S&P 500 (52W)119.14%

Year-to-Date Return97.10%

5-Day Price Return-5.64%

EPS Normalized (Annual)$-3.19

ROA (5Y Avg)-70.37%

Net Profit Margin (Annual)-139.81%

Month-to-Date Return20.71%

Cash Flow / Share (TTM)$-4.08

EBITD / Share (Annual)$-2.59

Operating Margin (Annual)-113.73%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-324.81%

LT Debt / Equity (Quarterly)4.77x

EPS Basic Excl Extra (TTM)$-1.98

P/B Ratio (Annual)25.38x

Inventory Turnover (TTM)1.09x

Pretax Margin (TTM)-51.98%

Book Value / Share (Annual)$0.37

Price vs S&P 500 (13W)51.69%

Beta1.54x

P/FCF (Annual)695.92x

Revenue / Share (TTM)$3.75

ROE (TTM)-204.47%

52-Week Low$15.86

vGradeD

gGradeA

mGradeB

vgmGradeB

URGN Earnings Surprise History

Q2 25-1.05est. -0.83

Q3 25-0.69est. -0.68

Q4 25-0.53est. -0.51

Q1 26-0.47est. -0.48

Q2 26-0.28est. -0.27

URGN Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.21

4.29

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
URGNUroGen Pharma Ltd. Ordinary Shares	D	A	B	$46.36
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About UroGen Pharma Ltd. Ordinary Shares

UroGen Pharma is a biopharmaceutical company specializing in non-muscle invasive urothelial cancer treatments. The company commercializes two FDA-approved products—Jelmyto and Zusduri (both mitomycin-based)—which leverage its proprietary RTGel sustained-release technology to enhance therapeutic efficacy. Revenue is derived from United States sales of these approved oncology products.